首页> 外文期刊>Stem cells international >Human Amnion Epithelial Cell Therapy for Chronic Liver Disease
【24h】

Human Amnion Epithelial Cell Therapy for Chronic Liver Disease

机译:慢性肝病的人疗法上皮细胞疗法

获取原文
获取外文期刊封面目录资料

摘要

Liver fibrosis is a common consequence of chronic liver disease. Over time, liver fibrosis can develop into liver cirrhosis. Current therapies for liver fibrosis are limited, and liver transplant is the only curative therapy for patients who progress to end-stage disease. A potential approach to treat chronic liver disease with increasing interest is cell-based therapy. Among the multiple cell types which have been proposed for therapeutic uses, human amnion epithelial cells and amniotic fluid-derived mesenchymal cells are promising. These cells are highly abundant, and their use poses no ethical concern. Furthermore, they exert potent anti-inflammatory and antifibrotic effects in animal models of liver injury. This review highlights the therapeutic characteristics and discusses how human amnion epithelial cells can be utilised as a therapeutic tool for chronic liver disease.
机译:肝纤维化是慢性肝病的常见后果。随着时间的推移,肝纤维化可以发展成肝硬化。目前的肝纤维化疗法是有限的,肝移植是对终级疾病的患者的唯一疗法治疗。治疗慢性肝病随着较高兴趣治疗慢性肝病的潜在方法是基于细胞的疗法。在为治疗用途提出的多种细胞类型中,人嗜睡上皮细胞和刚性流体衍生的间充质细胞是有前途的。这些细胞非常丰富,它们的使用没有道德问题。此外,它们在肝损伤的动物模型中发挥有效的抗炎和抗灰度作用。本综述突出了治疗特征,并讨论了人类氨基中的上皮细胞如何用作慢性肝病的治疗工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号